Oxford University Press, USA
Neuroethics of Biomarkers: What the Development of Bioprediction Means for Moral Responsibility, Justice, and the Nature of Mental Disorder
Neuroethics of Biomarkers: What the Development of Bioprediction Means for Moral Responsibility, Justice, and the Nature of Mental Disorder
Regular price
$82.00 USD
Regular price
Sale price
$82.00 USD
Unit price
per
Shipping calculated at checkout.
Couldn't load pickup availability
Neuroscientists are mining nucleic acids, blood, saliva, and brain images in hopes of uncovering biomarkers that could help estimate risk of brain disorders like psychosis and dementia; though the science of bioprediction is young, its prospects are unearthing controversy about how
bioprediction should enter hospitals, courtrooms, or state houses. While medicine, law, and policy have established protocols for how presence of disorders should change what we owe each other or who we blame, they have no stock answers for the probabilities that bioprediction offers. The
Neuroethics of Biomarkers observes, however, that for many disorders, what we really care about is not their presence per se, but certain risks that they carry. The current reliance of moral and legal structures on a categorical concept of disorder (sick verses well), therefore, obscures difficult
questions about what types and magnitudes of probabilities matter. Baum argues that progress in the neuroethics of biomarkers requires the rejection of the binary concept of disorder in favor of a probabilistic one based on biological variation with risk of harm, which Baum names a Probability
Dysfunction. This risk-reorientation clarifies practical ethical issues surrounding the definition of mental disorder in the DSM-5 and the nosology of conditions defined by risk of psychosis and dementia. Baum also challenges the principle that the acceptability of bioprediction should depend
primarily on whether it is medically useful by arguing that biomarkers can also be morally useful through enabling moral agency, better assessment of legal responsibility, and fairer distributive justice. The Neuroethics of Biomarkers should be of interest to those within neuroethics, medical
ethics, and the philosophy of psychiatry.
Author: Matthew L. Baum
Publisher: Oxford University Press, USA
Published: 03/10/2016
Pages: 224
Binding Type: Hardcover
Weight: 1.10lbs
Size: 9.30h x 6.20w x 0.80d
ISBN: 9780190236267
bioprediction should enter hospitals, courtrooms, or state houses. While medicine, law, and policy have established protocols for how presence of disorders should change what we owe each other or who we blame, they have no stock answers for the probabilities that bioprediction offers. The
Neuroethics of Biomarkers observes, however, that for many disorders, what we really care about is not their presence per se, but certain risks that they carry. The current reliance of moral and legal structures on a categorical concept of disorder (sick verses well), therefore, obscures difficult
questions about what types and magnitudes of probabilities matter. Baum argues that progress in the neuroethics of biomarkers requires the rejection of the binary concept of disorder in favor of a probabilistic one based on biological variation with risk of harm, which Baum names a Probability
Dysfunction. This risk-reorientation clarifies practical ethical issues surrounding the definition of mental disorder in the DSM-5 and the nosology of conditions defined by risk of psychosis and dementia. Baum also challenges the principle that the acceptability of bioprediction should depend
primarily on whether it is medically useful by arguing that biomarkers can also be morally useful through enabling moral agency, better assessment of legal responsibility, and fairer distributive justice. The Neuroethics of Biomarkers should be of interest to those within neuroethics, medical
ethics, and the philosophy of psychiatry.
Author: Matthew L. Baum
Publisher: Oxford University Press, USA
Published: 03/10/2016
Pages: 224
Binding Type: Hardcover
Weight: 1.10lbs
Size: 9.30h x 6.20w x 0.80d
ISBN: 9780190236267
About the Author
Matthew L. Baum, DPhil, is an MD-PhD trainee at Harvard & MIT within the Division of Health Sciences & Technology and the Harvard Program in Neuroscience. He earned a DPhil from Oxford via his work at the Oxford Centre for Neuroethics and the Ethox Center as a Rhodes Scholar. He holds an MSc in Neuroscience from Trinity College Dublin, where he studied as a Mitchell Scholar. He has also served as the student/post-doc representative to the board of the International Neuroethics Society.
